GlassScriptPhysician profile
Luisa T Manestar
NPI 1851426621
$3,490.26
in general payments reported to CMS, 2019-2025
35 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $454 · 2021: $671 · 2022: $518 · 2023: $470 · 2024: $490 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,216.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $230.47 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $220.93 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $205.69 | 2019-2025 | |
| Lilly USA, LLC | $199.94 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $172.97 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $128.21 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $126.40 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $110.53 | 2019-2022 | |
| Abbvie INC. | $108.26 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.06 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $64.49 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $54.30 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $53.55 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.71 | 2025 | Caplyta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $45.24 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $44.78 | 2022 | |
| Nevro Corp. | $43.85 | 2023-2024 | Senza |
| Sunovion Pharmaceuticals INC. | $41.75 | 2019-2022 | |
| Boston Scientific Corporation | $39.26 | 2024-2025 | General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.73 | 2021-2023 | Ofev |
| Exact Sciences Corporation | $27.78 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $26.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $23.62 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.11 | 2024 | Xifaxan |
| Lundbeck LLC | $18.32 | 2024 | Rexulti |
| Irhythm Technologies, INC. | $15.85 | 2023 | Zio Xt Patch |
| Horizon Therapeutics Plc | $13.69 | 2021 | |
| Biogen, INC. | $13.45 | 2021 | |
| Amarin Pharma, INC. | $12.95 | 2019 | |
| Allergan, INC. | $12.80 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.96 | 2022 | |
| Esperion Therapeutics, INC. | $11.26 | 2021 | |
| Medtronic Minimed, INC. | $11.06 | 2020 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luisa Manestar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.